Delta-Fly Pharma Updates on DFP-10917 Clinical Trials

MT Newswires Live

2025/11/06

Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.

Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.

A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.

In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581057432"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581057432\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581057432?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581057432","market":"nz","top_or_hot":-1,"title":"Delta-Fly Pharma Updates on DFP-10917 Clinical Trials","media":"MT Newswires Live","content":"<html><body><p> Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.</p><p>A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.</p><p>In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delta-Fly Pharma Updates on DFP-10917 Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelta-Fly Pharma Updates on DFP-10917 Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-06 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.</p><p>A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.</p><p>In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFP","symbol_name":"Flaherty & Crumrine Dynamic","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2581057432","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581057432","pubTimestamp":1762421215,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Delta-Fly Pharma  said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFP":"Flaherty & Crumrine Dynamic"},"translate_title":"Delta-Fly Pharma更新DFP-10917临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFP":1.5},"content_text":"Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}